NCT03833700 is a Phase 1 clinical trial of E7386 in Solid Neoplasms, sponsored by Eisai Co., Ltd..

Who is sponsoring NCT03833700?

NCT03833700 is sponsored by Eisai Co., Ltd..

What drugs are being tested in NCT03833700?

Interventions in NCT03833700: E7386.

What condition does NCT03833700 study?

NCT03833700 studies Solid Neoplasms, Colorectal Neoplasms, Gastrointestinal Tumors.

Is NCT03833700 still recruiting?

NCT03833700 is currently active, enrolled. Last updated 27 February 2026.

Last reviewed 2026-02-27 · How we verify

NCT03833700

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

Active, enrolled Phase 1 Last updated 27 February 2026

What this trial tests

Phase 1 trial testing E7386 in Solid Neoplasms in 70 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

5 March 2019

Primary endpoint
31 March 2027

31 March 2027

Quick facts

Lead sponsor	Eisai Co., Ltd.
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	70
Start date	5 March 2019
Primary completion	31 March 2027
Estimated completion	31 March 2027
Sites	8 locations across Japan

Drugs / interventions tested

E7386 — full drug profile →

Conditions studied

Solid Neoplasms — all drugs for Solid Neoplasms →
Colorectal Neoplasms — all drugs for Colorectal Neoplasms →
Gastrointestinal Tumors — all drugs for Gastrointestinal Tumors →

Sponsor

Eisai Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Solid Neoplasms or Colorectal Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will be conducted to assess the safety and tolerability of E7386 in participants with solid tumor including CRC.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities.
Liu J, Xiao Q, Xiao J, Niu C, et al · · 2022 · cited 1756× · PMID 34980884 · DOI 10.1038/s41392-021-00762-6
WNT as a Driver and Dependency in Cancer.
Parsons MJ, Tammela T, Dow LE. · · 2021 · cited 202× · PMID 34518209 · DOI 10.1158/2159-8290.cd-21-0190
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances.
Xue C, Chu Q, Shi Q, Zeng Y, et al · · 2025 · cited 103× · PMID 40180907 · DOI 10.1038/s41392-025-02142-w
Wnt/β-catenin mediated signaling pathways in cancer: recent advances, and applications in cancer therapy.
Wu X, Que H, Li Q, Wei X. · · 2025 · cited 33× · PMID 40495229 · DOI 10.1186/s12943-025-02363-1
Wnt Signaling Pathways in Keratinocyte Carcinomas.
Lang CMR, Chan CK, Veltri A, Lien WH. · · 2019 · cited 31× · PMID 31438551 · DOI 10.3390/cancers11091216
Desmoid Tumors: Current Perspective and Treatment.
Mangla A, Agarwal N, Schwartz G. · · 2024 · cited 20× · PMID 38270798 · DOI 10.1007/s11864-024-01177-5
Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?
de Pellegars-Malhortie A, Picque Lasorsa L, Mazard T, Granier F, et al · · 2024 · cited 12× · PMID 39065798 · DOI 10.3390/ph17070949
Next-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches.
Eghbali S, Heumann TR. · · 2025 · cited 11× · PMID 39858016 · DOI 10.3390/cancers17020236

Verify or expand the search:

Other trials of E7386

Trials testing the same drug.

NCT05091346 — A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors · Phase 1, PHASE2 · completed
NCT04840927 — A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets · Phase 1 · withdrawn
NCT04008797 — A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor · Phase 1, PHASE2 · active not recruiting
NCT03996226 — A Food-Effect Study of E7386 in Healthy Participants · Phase 1 · completed
NCT03264664 — Study of E7386 in Participants With Selected Advanced Neoplasms · Phase 1 · active not recruiting

Other recruiting trials for Solid Neoplasms

Currently open trials in the same condition.

NCT04078295 — A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor · Phase 1, PHASE2 · active not recruiting

Other Eisai Co., Ltd. trials

Trials by the same sponsor.

NCT07515014 — A Study of E6742 in Participants With Systemic Lupus Erythematosus · Phase 2 · not yet recruiting
NCT06793709 — A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast G · recruiting
NCT06657378 — A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized T · recruiting
NCT06322667 — A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab · recruiting
NCT05633108 — A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03833700 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eisai Co., Ltd.
Last refreshed: 27 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03833700.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing